Literature DB >> 25618594

Oxytocin enhances the expression of morphine-induced conditioned place preference in rats.

Mahsa Moaddab1, Brian I Hyland2, Colin H Brown3.   

Abstract

Drug addiction is characterized by drug-seeking and drug-taking and has devastating consequences on addicts as well as on society. Environmental contexts previously associated with drug use can elicit continued drug use and facilitate relapse. Accumulating evidence suggests that the neuropeptide oxytocin might be a potential treatment for behavioral disorders, including drug addiction. Here, we investigated the effects of central oxytocin administration on the acquisition and expression of morphine-induced conditioned place preference (CPP), a model for measuring the rewarding effects of drugs of abuse, in male Wistar rats. Intracerebroventricular (ICV) administration of oxytocin (0.2μg) or the specific oxytocin receptor antagonist (OTA), desGly-NH2, d(CH2)5[Tyr(Me)(2), Thr(4)] OVT, (0.75μg), on the conditioning days did not affect the acquisition of morphine-induced CPP. By contrast, ICV oxytocin, but not OTA, administration immediately prior to the post-conditioning session enhanced the expression of morphine-induced CPP, possibly by activation of oxytocin receptors in the nucleus accumbens shell (NAcSh). The oxytocin enhancement of morphine-induced CPP was not associated with any changes in the locomotor activity of morphine-conditioned rats. Together, these data suggest that central administration of exogenous oxytocin enhances the expression of morphine-induced CPP, at least in part, via activation of oxytocin receptors within the NAcSh.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Addiction; Conditioned place preference; Morphine; Nucleus accumbens shell; Oxytocin; Reward

Mesh:

Substances:

Year:  2015        PMID: 25618594     DOI: 10.1016/j.psyneuen.2015.01.003

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  10 in total

Review 1.  Targeting the Oxytocin System to Treat Addictive Disorders: Rationale and Progress to Date.

Authors:  Mary R Lee; Matthew C H Rohn; Gianluigi Tanda; Lorenzo Leggio
Journal:  CNS Drugs       Date:  2016-02       Impact factor: 5.749

Review 2.  Oxytocin for the treatment of drug and alcohol use disorders.

Authors:  Mary R Lee; Elise M Weerts
Journal:  Behav Pharmacol       Date:  2016-12       Impact factor: 2.293

Review 3.  Oxytocin and opioid addiction revisited: old drug, new applications.

Authors:  Panos Zanos; Polymnia Georgiou; Carol Weber; Fiona Robinson; Christos Kouimtsidis; Ramin Niforooshan; Alexis Bailey
Journal:  Br J Pharmacol       Date:  2017-04-06       Impact factor: 8.739

4.  Oxytocin receptor neurotransmission in the dorsolateral bed nucleus of the stria terminalis facilitates the acquisition of cued fear in the fear-potentiated startle paradigm in rats.

Authors:  Mahsa Moaddab; Joanna Dabrowska
Journal:  Neuropharmacology       Date:  2017-04-26       Impact factor: 5.250

5.  Oxytocin Receptor Activation Rescues Opioid-Induced Respiratory Depression by Systemic Fentanyl in the Rat.

Authors:  Allison Doyle Brackley; Glenn M Toney
Journal:  J Pharmacol Exp Ther       Date:  2021-05-14       Impact factor: 4.402

Review 6.  Effect of early life social adversity on drug abuse vulnerability: Focus on corticotropin-releasing factor and oxytocin.

Authors:  Michael T Bardo; Lindsey R Hammerslag; Samantha G Malone
Journal:  Neuropharmacology       Date:  2021-04-13       Impact factor: 5.273

7.  The role of orgasm in the development and shaping of partner preferences.

Authors:  Genaro A Coria-Avila; Deissy Herrera-Covarrubias; Nafissa Ismail; James G Pfaus
Journal:  Socioaffect Neurosci Psychol       Date:  2016-10-25

8.  Oxytocin Attenuates Expression, but Not Acquisition, of Sucrose Conditioned Place Preference in Rats.

Authors:  Devon Patel; Megana Sundar; Eva Lorenz; Kah-Chung Leong
Journal:  Front Behav Neurosci       Date:  2020-12-15       Impact factor: 3.558

9.  The Non-Peptide Arginine-Vasopressin v1a Selective Receptor Antagonist, SR49059, Blocks the Rewarding, Prosocial, and Anxiolytic Effects of 3,4-Methylenedioxymethamphetamine and Its Derivatives in Zebra Fish.

Authors:  Luisa Ponzoni; Daniela Braida; Gianpietro Bondiolotti; Mariaelvina Sala
Journal:  Front Psychiatry       Date:  2017-08-14       Impact factor: 4.157

10.  The effects of intranasal oxytocin on reward circuitry responses in children with autism spectrum disorder.

Authors:  R K Greene; M Spanos; C Alderman; E Walsh; J Bizzell; M G Mosner; J L Kinard; G D Stuber; T Chandrasekhar; L C Politte; L Sikich; G S Dichter
Journal:  J Neurodev Disord       Date:  2018-03-27       Impact factor: 4.025

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.